脐带间充质干细胞治疗17例类风湿性关节炎患者的临床疗效观察

Therapeutic efficacy of umbilical cord mesenchymal stem cells for rheumatoid arthritis in seventeen patients

目的:本文应用脐带间充质干细胞(Umbilical Cord Mesenchymal stem cell,UC-MSC)探讨治疗RA的疗效,为临床治疗RA寻找新途径。方法:采用脐带间充质干细胞静脉输注的方式,细胞数为1×107/人次,对17例RA患者进行疗效观察。2例类风湿合并强直性脊柱炎病人同时还采用局部注射。结果:全部患者在饮食、睡眠、体力、疲劳等临床症状方面均有明显改善;全部患者满足ACR20标准,15例患者28个关节的疾病活动度评分(DAS28)<3.2;12例患者满足ACR70标准,DAS28评分<2.6;1例JRA患者,脐带间充质干细胞治疗4天后发热、皮疹消退,多关节疼痛得到控制。治疗前后患者血常规、肝肾功、血清免疫球蛋白及补体C3、C4检测结果无显著变化。结论:脐带间充质干细胞具有免疫调节、阻止炎性介质释放、减轻组织损伤等重要作用,可减轻和缓解RA的临床症状,且脐带间充质干细胞治疗对人体各项指标无明显改变,安全性很好,为临床治疗RA,寻找到一条新途径。

Objective：To explore a novel effective therapy for rheumatoid arthritis through evaluating the effect of umbilical cord mesenchymal stem cells （UC-MSC） in treatment of rheumatoid arthritis.Methods：A dose of 1×107 UC-MSCs were transfused into 17 patients individually.Besides,two patients suffering from complication of Ankylosing spondylitis received local injection at the same time.Results：All the parameters were improved after the treatment.28 arthrosis of 15 patients were ameliorated by average of DAS28 score 3.2 according to ACR20,12 patients with DAS28 less than 2.6 according to ACR70.Four days after the treatment,one patient with complication of juvenile rheumatoid arthritis was rid of fever and skin rash.No significant difference was observed when comparing post-treatment with pre-treatment of biochemical parameters,which contains blood routine,Hepatic function,renal function,serum immunoglobulin,complement C3/C4.Conclusion：UC-MSCs can regulate the immune system,reduce inflammatory mediator release,and relieve suffering from RA patients.It is safe for RA patients to be treated with UC-MSCs.UC-MSCs may be a novel potential therapeutic application in RA.